Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

Researchers Develop Label-Free Automatic Cancer Diagnostics

October 25, 2013 By Ruhr-Universität Bochum

Researchers at the Ruhr-Universität Bochum (RUB) have developed a new spectroscopic method to support pathologists in diagnosing cancer. In the Journal of Biophotonics and the Analyst they compared conventional procedures for colon cancer identification with a novel method called label-free spectral histopathology. “Contrary to previous methods we no longer have to stain the tissue in order to detect cancer,” says Professor Klaus Gerwert from the Protein Research Unit Ruhr within Europe (PURE) at the RUB. “In the future, this will give us the opportunity to classify a tissue sample automatically as being either normal or diseased.”

A classic H&E-(haematoxylin-eosin)-stained section is shown on the right. FTIR imaging (left) achieves a resolution of ten micrometres at maximum; spectral histopathology reveals the existence of alterations in the crypts (red), i.e. depressions in the colon, which are confirmed by immunohistochemical fluorescent stain (P53).Diagnosis: colon cancer
Today pathologists slice tissue obtained from biopsies into thin sections, stain them chemically, and eventually identify colon cancer by visual inspection under the microscope. This is usually done at an advanced stage of the disease, and the method provides no information about the molecular causes of the tumour. However, the method of spectral histopathology (SHP) established at the RUB Department of Biophysics captures molecular alterations directly in the tissues, especially changes of proteins. It works without any labelling agents, such as fluorescent dyes. SHP may even detect alterations occurring in early tumour stages. Since the analysis uses light beams, SHP is not limited to thin sections of biopsy specimens – in fact, one can apply the method directly in live tissue, where it allows to inspect a site of interest with the aid of fibre-optics. “In the future, we intend to work together with clinical partners and apply spectral histopathology to patients directly via endoscopes,” says Klaus Gerwert.

How spectral histopathology works
In SHP, researchers record spatially resolved vibration spectra of a tissue using either an infrared or a Raman microscope. A vibration spectrum reflects the condition of all proteins in a tissue at the site measured. Alterations induced by cancer are reflected in the respective spectrum. The spectrum is thus representative of the status of the sample, just like a fingerprint is characteristic of an individual person. Approximately ten million infrared spectra are usually recorded to produce one single tissue image. Using sophisticated computational image analysis procedures, researchers compare these spectra with a reference database. This database contains spectra of already known tissues and tumours, and has been established in the PURE consortium as a collaboration between pathologists, biophysicists and bioinformaticians. The analytical programme allocates each spectrum to tissue types that have been stored in the database, represented by a specific colour—just like an offender who can be identified by comparing his fingerprints with previous database entries. This produces a spatially resolved annotated image of the colon tissue section. Both PURE members, Professor Andrea Tannapfel, Director of the Pathology Institute at the RUB, and Professor Axel Mosig, Head of Bioinformatics at the Department of Biophysics, made the essential contributions in creating the database and the evaluation algorithm. By now, the evaluation programme will run on any commercial laptop.

Comparison with conventional tumour detection methods
In order to test the sensitivity and specificity of spectral histopathology, the RUB team compared SHP with classical immunohistochemical methods, in which tumours are identified with the aid of fluorescent labels. “The results match perfectly. It demonstrates impressively that spectral histopathology is capable of determining changes in tissue composition with high sensitivity and in an automated fashion,” says Prof Gerwert. In fact, sensitivity and specificity of the method exceed 95 per cent. By extending their method to include Raman imaging, the RUB team achieved a higher spatial resolution than they could with infrared imaging, however, at the cost of prolonged measurement time. “Both methods complement each other excellently,” comments Klaus Gerwert. “Infrared spectroscopy gives you a rapid overview of the entire tissue section. We can then analyse suspicious regions in more detail by applying Raman imaging.” Raman analysis, for example,

The project receives financial support from the regional state of North-Rhine Westphalia in the scope of the European Protein Research Institute PURE, whose speaker is Prof Gerwert.

Related Articles Read More >

A photo of Capstan Medical's mitral valve implant, which uses nitinol.
Capstan Medical’s R&D head discusses the heart valve and robotics startup’s tech, engineering challenges and solutions, advice for others in medtech and how to join his team
An illustration of a neurosurgeon using a robotic endoscope to remove a brain tumor.
MDO Nitinol Innovation Special Report
A photo of Highridge Medical CEO Rebecca Whitney.
Highridge Medical is betting on this spine tech
A photo of the miniature Auxilium Biotechnologies implants made on the International Space Station.
Implants 3D-printed in space could enable nerve regeneration
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe